Literature DB >> 26213338

The use of the acute Pd/Pa drop after intracoronary nitroglycerin infusion to rule out significant FFR: CANICA (Can intracoronary nitroglycerin predict fractional flow reserve without adenosine?) multicenter study.

R Martin-Reyes1, J M de la Torre Hernandez2, J Franco-Pelaez1, R Lopez-Palop3, M Telleria Arrieta4, I J Amat Santos5, P Carrillo Saez3, A Sanchez-Recalde6, J C Sanmartin Pena4, T Garcia Camarero2, S Brugaletta7, F Gimeno de Carlos5, A Pinero1, D C Sorto Sanchez2, A Frutos3, G Lasa Larraya4, F Navarro1, J Farre1.   

Abstract

OBJECTIVE: Functional assessment of coronary artery stenosis is performed by measuring the fractional flow reserve (FFR) under hyperemic conditions (Adenosine). However, the use of adenosine portends limitations.
OBJECTIVE: We sought to investigate the relationship and correlation between FFR and the Pd/Pa value obtained just after the intracoronary infusion (acute drop) of nitroglycerin (Pd/Pa-NTG) and if this parameter enhances diagnostic accuracy for FFR prediction compared to the resting baseline Pd/Pa.
METHODS: We conducted a multicenter study including prospectively patients presenting intermediate coronary artery stenosis (30-70%) evaluated with pressure wire. Resting baseline Pd/Pa, Pd/Pa-NTG and FFR were measured.
RESULTS: 283 patients (335 lesions) were included. Resting baseline Pd/Pa value was 0.72 to 1.0 (0.93 ± 0.04), Pd/Pa-NTG was 0.60 to 1.0 (0.87 ± 0.07) and FFR 0.55 to 1.0 (0.83 ± 0.08). The ROC curves for resting baseline Pd/Pa and for Pd/Pa-NTG, using a FFR ≤ 0.80 showed an AUC of 0.88 (95% CI: 0.84-0.92, P < 0.001) and 0.94 (95% CI: 0.92-0.96, P < 0.001) respectively. The optimal cutoff values of resting baseline Pd/Pa and Pd/Pa-NTG for an FFR > 0.80, were >0.96 and >0.88, respectively. These values were present in a 29.8% (n = 100) and a 47.1% (n = 158), of the total lesions. Scatter plots showed a better correlation and agreement points with Pd/Pa-NTG than resting baseline Pd/Pa. The cutoff value of Pd/Pa-NTG > 0.88 showed an excellent NPV (96.2% for FFR > 0.8 and 100% for FFR > 0.75) and sensitivity (95% for FFR > 0.8 and 100% for FFR > 0.75) which were consistently high across all the subgroups analysis.
CONCLUSION: The cutoff value of acute Pd/Pa-NTG > 0.88 has a high NPV meaning adenosine-FFR can be avoided in almost half of lesions.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  fractional flow reserve; microcirculation; pressure wire

Mesh:

Substances:

Year:  2015        PMID: 26213338     DOI: 10.1002/ccd.25983

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  5 in total

1.  Detrimental effects of nitroglycerin use during regadenoson vasodilator stress testing: A cautionary tale.

Authors:  Vineet Agrawal; Carolann Hosey; Gary T Smith; Chirayu Shah
Journal:  J Nucl Cardiol       Date:  2018-01-23       Impact factor: 5.952

2.  Efficacy and Safety of High-Dose Intracoronary Adenosine Injection in Fractional Flow Reserve Assessment.

Authors:  Chien-Boon Jong; Min-Tsun Liao; Tsui-Shan Lu; Shih-Wei Meng; Chun-Kai Chen; Ya-Chin Tsai; Jui-Cheng Kuo; Chih-Cheng Wu
Journal:  Acta Cardiol Sin       Date:  2022-09       Impact factor: 1.800

Review 3.  Fractional flow reserve-guided management in stable coronary disease and acute myocardial infarction: recent developments.

Authors:  Colin Berry; David Corcoran; Barry Hennigan; Stuart Watkins; Jamie Layland; Keith G Oldroyd
Journal:  Eur Heart J       Date:  2015-06-02       Impact factor: 29.983

Review 4.  Fractional flow reserve: a clinical perspective.

Authors:  David Corcoran; Barry Hennigan; Colin Berry
Journal:  Int J Cardiovasc Imaging       Date:  2017-06-02       Impact factor: 2.357

5.  Efficacy of coronary fractional flow reserve using contrast medium compared to adenosine.

Authors:  Selim Topcu; Ibrahim Halil Tanboğa; Enbiya Aksakal; Uğur Aksu; Oktay Gulcu; Oğuzhan Birdal; Arif Arısoy; Arzu Kalaycı; Fatih Rifat Ulusoy; Serdar Sevimli
Journal:  Postepy Kardiol Interwencyjnej       Date:  2016-08-19       Impact factor: 1.426

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.